Eiko Lifesciences Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002696,
    "name": "Eiko Lifescience",
    "stock_name": "Eiko Lifescience",
    "full_name": "Eiko Lifesciences Ltd",
    "name_url": "stocks-analysis/eiko-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "52.20",
    "chg": -0.8,
    "chgp": "-1.51%",
    "dir": -1,
    "prev_price": "53.00",
    "mcapval": "73.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540204,
    "symbol": "",
    "ind_name": "Specialty Chemicals",
    "ind_code": 5,
    "indexname": "",
    "isin": "INE666Q01016",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "20.15 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/eiko-lifescience-1002696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Eiko Lifesciences: Analytical Reassessment Reflects Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-downgraded-to-sell-amid-mixed-financials-and-bearish-technicals-3740759",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/EikoLifescience_mojoScore_3740759.png",
        "date": "2025-12-02 08:58:57",
        "description": "Eiko Lifesciences, a player in the specialty chemicals sector, has undergone a revision in its market assessment following a detailed evaluation of its financial performance, valuation metrics, and technical indicators. The recent changes highlight a complex interplay of strong quarterly results contrasted with subdued long-term returns and evolving technical trends, prompting a nuanced view of the stock’s outlook."
      },
      {
        "title": "How has been the historical performance of Eiko Lifescience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-eiko-lifescience-3739370",
        "imagepath": "",
        "date": "2025-12-01 23:33:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Growth</strong></p>\n<p>Between March 2018 and March 2025, Eiko Lifescience’s net sales surged from ₹2.34 crores to ₹37.66 crores, marking a substantial increase that underscores the company’s expanding market presence. Total operating income mirrored this growth, rising from ₹2.34 crores to ₹37.66 crores over the same period. Despite this impressive top-line expansion, the company’s profitability experienced fluctuations. Operating profit before depreciation and interest (PBDIT) excluding other income was positive at ₹0.35 crores in March 2018 but turned negative in the years leading up to March 2020, reflecting operational challenges. However, by March 2025, the company returned to profitability with a PBDIT of ₹2.76 crores, supported by an additional ₹0.72 crores ..."
      },
      {
        "title": "Why is Eiko Lifescience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifescience-fallingrising-3734391",
        "imagepath": "",
        "date": "2025-11-28 00:42:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>The stock’s fall on 27-Nov is part of a short-term downward trend, with a one-week return of -3.37%, contrasting sharply with the Sensex’s modest gain of 0.10% over the same period. This divergence highlights Eiko Lifesciences’ relative weakness in the current market environment. Although the stock has managed a slight positive return of 1.14% over the past month, this is almost on par with the Sensex’s 1.11%, indicating that recent gains have been limited and not sufficient to offset broader losses.</p>\n<p>More concerning is the year-to-date (YTD) performance, where Eiko Lifesciences has declined by 18.25%, while the Sensex has risen by 9.70%. Over the last one year, the stock has fallen by 15.96%, whereas the benchmark index has appr..."
      },
      {
        "title": "Eiko Lifesciences Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eiko-lifesciences-upgraded-to-hold-as-technicals-improve-amid-strong-quarterly-performance-3727920",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EikoLifescience_mojoScore_3727920.png",
        "date": "2025-11-25 08:56:13",
        "description": "Eiko Lifesciences, a player in the Specialty Chemicals sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. This shift comes amid a backdrop of strong quarterly results juxtaposed with subdued longer-term returns, prompting a nuanced reassessment of the company’s investment profile."
      },
      {
        "title": "Why is Eiko Lifescience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifescience-fallingrising-3709371",
        "imagepath": "",
        "date": "2025-11-17 23:37:58",
        "description": "As of 17-Nov, Eiko Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 53.10, reflecting a decrease of Rs 1.65 or 3.01%. The stock has underperformed its sector by 3.43% today and has been on a consecutive downward trend for the last two days, with a total drop of 3.47% in that period. Although the stock opened with a gain of 3.18% and reached an intraday high of Rs 56.49, it also touched a low of Rs 52.68, indicating significant volatility. The stock's performance over the past week shows a decline of 6.63%, while it has gained 4.63% over the past month. However, year-to-date, it has fallen by 15.36%, contrasting with the Sensex's gain of 8.72% during the same period. The stock is currently trading above its 200-day moving average but below its shorter-term moving averages, suggesting mixed signals regarding its trend. Additionally, there has been a notable decrease in investor p..."
      },
      {
        "title": "How has been the historical performance of Eiko Lifescience?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-eiko-lifescience-3709158",
        "imagepath": "",
        "date": "2025-11-17 23:21:41",
        "description": "Answer:\nThe historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, culminating in a positive trend by March 2025.\n\nBreakdown:\nEiko Lifescience's net sales increased dramatically from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 2.34 Cr in March 2018 to 37.66 Cr in March 2025. The company's total expenditure also grew, but at a slower pace, from 1.99 Cr in March 2018 to 34.90 Cr in March 2025, leading to an operating profit (PBDIT) of 3.48 Cr in March 2025, a significant recovery from a loss of 4.50 Cr in March 2020. Profit before tax reached 2.92 Cr in March 2025, compared to a loss of 4.93 Cr in March 2020, and profit after tax improved to 2.18 Cr from a loss of 3.62 Cr in March 2020. The consolidated net profit for March 2025 was 2.11 Cr, a not..."
      },
      {
        "title": "Is Eiko Lifescience overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-eiko-lifescience-overvalued-or-undervalued-3700324",
        "imagepath": "",
        "date": "2025-11-14 08:12:40",
        "description": "As of 13 November 2025, Eiko Lifescience's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued. Key ratios include a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which suggests that the stock is relatively inexpensive compared to its growth prospects.\n\nIn comparison to its peers, Eiko Lifescience's PE ratio is lower than Bajaj Finance's 34.18 and significantly better than the life insurance sector's 11.18, which is categorized as very attractive. Additionally, while Bajaj Finserv is considered expensive with a PE of 33.91, Eiko's valuation appears more favorable. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year returns, the company's attractive valuation metrics suggest potential for future growth...."
      },
      {
        "title": "Why is Eiko Lifescience falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-eiko-lifescience-fallingrising-3677613",
        "imagepath": "",
        "date": "2025-11-06 23:38:48",
        "description": "As of 06-Nov, Eiko Lifesciences Ltd's stock price is currently at Rs 57.49, reflecting a decline of Rs 4.54 or 7.32%. The stock has recently experienced a trend reversal, falling after four consecutive days of gains. Although it opened with a gain of 3.58% today and reached an intraday high of Rs 64.25, it also touched a low of Rs 57.03, indicating high volatility with an intraday fluctuation of 5.95%. The stock has outperformed the sector over the past week and month, with returns of +9.13% and +12.24%, respectively, but it has underperformed today by 6.49%. Additionally, Eiko Lifesciences is trading above all its moving averages, and there has been a significant increase in investor participation, with delivery volume rising by 408.71% compared to the five-day average.\n\nIn the broader market context, while Eiko Lifesciences has shown strong short-term performance relative to the Sensex, which declined by ..."
      },
      {
        "title": "Eiko Lifesciences Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eiko-lifesciences-forms-golden-cross-signaling-potential-bullish-breakout-3676340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EikoLifescience_goldencross_3676340.png",
        "date": "2025-11-06 18:00:32",
        "description": "Eiko Lifesciences has recently experienced a Golden Cross, indicating potential upward momentum in its stock. Despite a year-to-date decline, the company has shown a 12.24% increase over the past month, outperforming the Sensex. Technical indicators suggest a possible shift in market sentiment for the microcap firm."
      }
    ],
    "total": 463,
    "sid": "1002696",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/eiko-lifesciences-1002696"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "30-Jan-2026",
      "details": "Newspaper publication of Un-audited Financial results (standalone & Consolidated) for Quarter and Nine- Months ended on 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th January 2026",
      "datetime": "29-Jan-2026",
      "details": "Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and amendments thereto this is to inform that the Meeting of the Board of Directors of the Company held today i.e. on Thursday 29th January 2026 Board inter-alia considered and approved Unaudited Financial Results (Standalone & Consolidated basis) for the Quarter ended 31st December 2025. The Statutory Auditors have carried out a Limited Review of the Unaudited Financial Results for the Quarter ended 31st December 2025. Further Pursuant to the Regulation 33 of the Listing Regulations we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company. The Meeting was commenced at 12: 30 PM and concluded at 13:00 PM.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Meeting Scheduled For Quarterly Results For The Quarter Ended 31St December 2025",
      "datetime": "16-Jan-2026",
      "details": "Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve Unaudited standalone and consolidated FInancial results for quarter ended 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has declared <strong>2%</strong> dividend, ex-date: 20 Sep 17",
          "dt": "2017-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Eiko Lifesciences Ltd has announced <strong>2:3</strong> rights issue, ex-date: 07 Jul 23",
          "dt": "2023-07-07",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Eiko Lifesciences: Analytical Reassessment Reflects Mixed Financial and Technical Signals

2025-12-02 08:58:57

Eiko Lifesciences, a player in the specialty chemicals sector, has undergone a revision in its market assessment following a detailed evaluation of its financial performance, valuation metrics, and technical indicators. The recent changes highlight a complex interplay of strong quarterly results contrasted with subdued long-term returns and evolving technical trends, prompting a nuanced view of the stock’s outlook.

How has been the historical performance of Eiko Lifescience?

2025-12-01 23:33:04

Revenue and Profitability Growth Between March 2018 and March 2025, Eiko Lifescience’s net sales surged from ₹2.34 crores to ₹37.66 crores, marking a substantial increase that underscores the company’s expanding market presence. Total operating income mirrored this growth, rising from ₹2.34 crores to ₹37.66 crores over the same period. Despite this impressive top-line expansion, the company’s profitability experienced fluctuations. Operating profit before depreciation and interest (PBDIT) excluding other income was positive at ₹0.35 crores in March 2018 but turned negative in the years leading up to March 2020, reflecting operational challenges. However, by March 2025, the company returned to profitability with a PBDIT of ₹2.76 crores, supported by an additional ₹0.72 crores ...

Why is Eiko Lifescience falling/rising?

2025-11-28 00:42:57

Recent Price Movement and Market Context The stock’s fall on 27-Nov is part of a short-term downward trend, with a one-week return of -3.37%, contrasting sharply with the Sensex’s modest gain of 0.10% over the same period. This divergence highlights Eiko Lifesciences’ relative weakness in the current market environment. Although the stock has managed a slight positive return of 1.14% over the past month, this is almost on par with the Sensex’s 1.11%, indicating that recent gains have been limited and not sufficient to offset broader losses. More concerning is the year-to-date (YTD) performance, where Eiko Lifesciences has declined by 18.25%, while the Sensex has risen by 9.70%. Over the last one year, the stock has fallen by 15.96%, whereas the benchmark index has appr...

Eiko Lifesciences Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-11-25 08:56:13

Eiko Lifesciences, a player in the Specialty Chemicals sector, has experienced a notable revision in its market evaluation, reflecting a complex interplay of financial performance, valuation metrics, and technical indicators. This shift comes amid a backdrop of strong quarterly results juxtaposed with subdued longer-term returns, prompting a nuanced reassessment of the company’s investment profile.

Why is Eiko Lifescience falling/rising?

2025-11-17 23:37:58

As of 17-Nov, Eiko Lifesciences Ltd is experiencing a decline in its stock price, currently at Rs 53.10, reflecting a decrease of Rs 1.65 or 3.01%. The stock has underperformed its sector by 3.43% today and has been on a consecutive downward trend for the last two days, with a total drop of 3.47% in that period. Although the stock opened with a gain of 3.18% and reached an intraday high of Rs 56.49, it also touched a low of Rs 52.68, indicating significant volatility. The stock's performance over the past week shows a decline of 6.63%, while it has gained 4.63% over the past month. However, year-to-date, it has fallen by 15.36%, contrasting with the Sensex's gain of 8.72% during the same period. The stock is currently trading above its 200-day moving average but below its shorter-term moving averages, suggesting mixed signals regarding its trend. Additionally, there has been a notable decrease in investor p...

How has been the historical performance of Eiko Lifescience?

2025-11-17 23:21:41

Answer: The historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, culminating in a positive trend by March 2025. Breakdown: Eiko Lifescience's net sales increased dramatically from 2.34 Cr in March 2018 to 37.66 Cr in March 2025, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 2.34 Cr in March 2018 to 37.66 Cr in March 2025. The company's total expenditure also grew, but at a slower pace, from 1.99 Cr in March 2018 to 34.90 Cr in March 2025, leading to an operating profit (PBDIT) of 3.48 Cr in March 2025, a significant recovery from a loss of 4.50 Cr in March 2020. Profit before tax reached 2.92 Cr in March 2025, compared to a loss of 4.93 Cr in March 2020, and profit after tax improved to 2.18 Cr from a loss of 3.62 Cr in March 2020. The consolidated net profit for March 2025 was 2.11 Cr, a not...

Is Eiko Lifescience overvalued or undervalued?

2025-11-14 08:12:40

As of 13 November 2025, Eiko Lifescience's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued. Key ratios include a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which suggests that the stock is relatively inexpensive compared to its growth prospects. In comparison to its peers, Eiko Lifescience's PE ratio is lower than Bajaj Finance's 34.18 and significantly better than the life insurance sector's 11.18, which is categorized as very attractive. Additionally, while Bajaj Finserv is considered expensive with a PE of 33.91, Eiko's valuation appears more favorable. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year returns, the company's attractive valuation metrics suggest potential for future growth....

Why is Eiko Lifescience falling/rising?

2025-11-06 23:38:48

As of 06-Nov, Eiko Lifesciences Ltd's stock price is currently at Rs 57.49, reflecting a decline of Rs 4.54 or 7.32%. The stock has recently experienced a trend reversal, falling after four consecutive days of gains. Although it opened with a gain of 3.58% today and reached an intraday high of Rs 64.25, it also touched a low of Rs 57.03, indicating high volatility with an intraday fluctuation of 5.95%. The stock has outperformed the sector over the past week and month, with returns of +9.13% and +12.24%, respectively, but it has underperformed today by 6.49%. Additionally, Eiko Lifesciences is trading above all its moving averages, and there has been a significant increase in investor participation, with delivery volume rising by 408.71% compared to the five-day average. In the broader market context, while Eiko Lifesciences has shown strong short-term performance relative to the Sensex, which declined by ...

Eiko Lifesciences Forms Golden Cross, Signaling Potential Bullish Breakout

2025-11-06 18:00:32

Eiko Lifesciences has recently experienced a Golden Cross, indicating potential upward momentum in its stock. Despite a year-to-date decline, the company has shown a 12.24% increase over the past month, outperforming the Sensex. Technical indicators suggest a possible shift in market sentiment for the microcap firm.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

30-Jan-2026 | Source : BSE

Newspaper publication of Un-audited Financial results (standalone & Consolidated) for Quarter and Nine- Months ended on 31st December 2025.

Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th January 2026

29-Jan-2026 | Source : BSE

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and amendments thereto this is to inform that the Meeting of the Board of Directors of the Company held today i.e. on Thursday 29th January 2026 Board inter-alia considered and approved Unaudited Financial Results (Standalone & Consolidated basis) for the Quarter ended 31st December 2025. The Statutory Auditors have carried out a Limited Review of the Unaudited Financial Results for the Quarter ended 31st December 2025. Further Pursuant to the Regulation 33 of the Listing Regulations we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company. The Meeting was commenced at 12: 30 PM and concluded at 13:00 PM.

Board Meeting Intimation for Meeting Scheduled For Quarterly Results For The Quarter Ended 31St December 2025

16-Jan-2026 | Source : BSE

Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 inter alia to consider and approve Unaudited standalone and consolidated FInancial results for quarter ended 31st December 2025

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Eiko Lifesciences Ltd has declared 2% dividend, ex-date: 20 Sep 17

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

Eiko Lifesciences Ltd has announced 2:3 rights issue, ex-date: 07 Jul 23

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."